OEC signs fluoroscope deal with Genzyme:
This article was originally published in Clinica
Genzyme of Cambridge, Massachusetts, and OEC Medical Systems of Salt Lake City, Utah, have reached an agreement for OEC to supply its Series 9600 cardiac mobile fluoroscope systems to Genzyme's cardiovascular units. At the same time the companies will now co-market their respective technologies in minimally-invasive cardiovascular surgery, through combined sales and training materials.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.